Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

• Artiva recognized for advancing AlloNK®, the first allogeneic, off-the-shelf NK cell therapy with an IND allowance for autoimmune disease
• AlloNK in combination with rituximab aims to be a safe and effective option for patients with lupus nephritis and has scalable potential for future applications in other autoimmune diseases

Excerpt from the Press Release:

SAN DIEGO–(BUSINESS WIRE)–Artiva Biotherapeutics, Inc., a clinical stage company with the mission to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry. This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale, and has the first IND clearance for an off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease. Artiva’s lead program, AlloNK (also known as AB-101), is an allogenic, non-genetically modified NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies or NK cell engagers. Seminal clinical data with autologous CAR-T cells suggests that deep B cell depletion can induce complete and long-lasting responses in patients with lupus nephritis. Artiva is leveraging AlloNK to enhance the ADCC activity of rituximab, a monoclonal antibody targeting CD20, to deplete B-cells in the treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis (LN).

“We are pleased to receive this BioTech Breakthrough Award for the role AlloNK could play in enhancing the ADCC activity of monoclonal antibodies in the treatment of lupus and other autoimmune diseases,” said Fred Aslan, M.D., CEO of Artiva. “The use of autologous CAR-T cells requires apheresis, likely hospitalization, and the potential for serious side effects. AlloNK is an off-the-shelf product with the potential for greater safety and accessibility for patients.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release